EUVIMEDEUVIMED entdecken
Open Access

Risk-Based Prophylactic Human Papillomavirus Vaccination of Heterosexual US Men Aged 27 to 45 Years for Prevention of Oropharyngeal Cancer

Anil K Chaturvedi, Gregory W Haber, Barry I Graubard, Li C Cheung, Maura L Gillison, Rebecca Landy iD

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Anil K Chaturvedi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Oropharyngeal Neoplasms, Vaccination. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: US National Cancer Institute, Cancer Prevention and Research Institute of Texas, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human papillomavirus (HPV) vaccination of US individuals aged 27–45 years is recommended through shared clinical decision-making. To enable shared decision-making, we used a microsimulation-based state-transition model to develop and validate a risk-prediction model to identify heterosexual men aged 27–45 years at high-risk of acquiring oral HPV-16 infections. A risk model for incident oral HPV-16 infections had good discrimination (AUC = 0.73) and calibration (ratio of expected to the observed number of incident oral HPV-16 infections through age 45 years [E/O] = 1.01) in internal cross-validation. Compared to vaccinating all men aged 27–45, vaccinating 44% of men with highest model-predicted risk would prevent 80% of incident oral HPV-16 infections through age 45 years and reduce the number needed to be vaccinated to prevent 1 infection by 45% (184 vs 100).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsPapillomavirus VaccinesOropharyngeal NeoplasmsVaccinationHumansMaleMiddle AgedAdultHeterosexualityUnited StatesHuman papillomavirus 16Risk Assessment

Stichwörter der Autor:innen

HPVHuman papillomavirusoropharyngeal cancerrisk stratificationvaccination

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Information Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland, USA.
  • Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Rebecca Landy

Förderung

  • US National Cancer Institute
  • Cancer Prevention and Research Institute of Texas
  • NIH

Zitieren

APA

Chaturvedi, A. K., Haber, G. W., Graubard, B. I., Cheung, L. C., Gillison, M. L., & Landy, R. (2026). Risk-Based Prophylactic Human Papillomavirus Vaccination of Heterosexual US Men Aged 27 to 45 Years for Prevention of Oropharyngeal Cancer. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag038

Vancouver

Chaturvedi AK, Haber GW, Graubard BI, Cheung LC, Gillison ML, Landy R. Risk-Based Prophylactic Human Papillomavirus Vaccination of Heterosexual US Men Aged 27 to 45 Years for Prevention of Oropharyngeal Cancer. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag038

BibTeX
@article{Chaturvedi2026,
  author = {Chaturvedi, Anil K and Haber, Gregory W and Graubard, Barry I and Cheung, Li C and Gillison, Maura L and Landy, Rebecca},
  title = {Risk-Based Prophylactic Human Papillomavirus Vaccination of Heterosexual US Men Aged 27 to 45 Years for Prevention of Oropharyngeal Cancer},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag038}
}
Kostenlos starten →